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Abstract 
Background: The emergence of Plasmodium falciparum resistance to artemisinins threatens to undermine the effec‑
tiveness of artemisinin‑based combination anti‑malarial therapy. Developing suitable drugs to replace artemisinins 
requires the identification of new compounds that display rapid parasite killing kinetics. However, no current meth‑
ods fully meet the requirements to screen large compound libraries for candidates with such properties. This study 
describes the development and validation of an in vitro parasite viability fast assay for identifying rapidly parasiticidal 
anti‑malarial drugs.
Methods: Parasite killing kinetics were determined by first culturing unlabelled erythrocytes with P. falciparum in the 
presence of anti‑malarial drugs for 24 or 48 h. After removing the drug, samples were added to erythrocytes pre‑
labelled with intracellular dye to allow their subsequent identification. The ability of viable parasites to re‑establish 
infection in labelled erythrocytes could then be detected by two‑colour flow cytometry after tagging of parasite DNA. 
Thus, double‑stained erythrocytes (with the pre‑labelled intracellular dye and the parasite DNA dye) result only after 
establishment of new infections by surviving parasites. The capacity of the test anti‑malarial drugs to eliminate viable 
parasites within 24 or 48 h could, therefore, be determined.
Results: The parasite viability fast assay could be completed within 48 h following drug treatment and distinguished 
between rapidly parasiticidal anti‑malarial drugs versus those acting more slowly. The assay was validated against ten 
standard anti‑malarial agents with known properties and results correlated well with established methods. An abbre‑
viated assay, suitable for adaption to medium–high throughput screening, was validated and applied against a set of 
20 compounds retrieved from the publically available Medicines for Malaria Venture ‘Malaria Box’.
Conclusion: The quantification of new infections to determine parasite viability offers important advantages over 
existing methods, and is amenable to medium–high throughput screening. In particular, the parasite viability fast 
assay allows discrimination of rapidly parasiticidal anti‑malarial candidates.
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Background
Plasmodium falciparum malaria remains a formida-
ble global health challenge. Although there have been 
recent improvements in mortality, 584,000 deaths were 
attributable to this parasite in 2013, and most of the vic-
tims were children [1].
At the end of the last century, P. falciparum resistance 
to the most clinically important anti-malarial agents 
had become widespread. The discovery and introduc-
tion of artemisinin-based combination therapy (ACT) 
salvaged the effectiveness of anti-malarial therapy. How-
ever, delayed parasite clearance in response to ACT has 
been observed clinically, and the development of parasite 
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resistance to these agents should be anticipated [2]. 
The loss of artemisinin efficacy would threaten recent 
advances in malaria mortality and morbidity and com-
promise the malaria eradication agenda [3].
Artemisinins are rapidly parasiticidal, quickly relieving 
malarial symptoms and minimizing the within-patient 
window of opportunity for resistant parasite selection 
and subsequent dissemination [4]. Replacement of arte-
misinins requires the identification of new drugs with 
similar rapid parasite killing kinetics. Ideally, such prop-
erties need to be identified in the early stages of the drug 
development process. However, no current methods fully 
meet the requirements to screen large compound librar-
ies for rapidly parasiticidal anti-malarial drug candidates.
Standard in  vitro parasite growth inhibition assays 
expose parasites to an anti-malarial drug for a defined 
period of time and determine the remaining viable para-
sites by labelling nucleic acids or measuring enzymatic 
activity. However, these methods do not allow direct 
determination of the rapidity of parasite killing—metab-
olism is not always a good surrogate of parasite viabil-
ity, and the reliability of such tests depends on the drug 
mechanism of action [5, 6]. Recently, a number of differ-
ent approaches have been proposed for the assessment of 
parasite viability after drug treatment [7–10]. However, 
none of these methods provide a complete time course 
for parasite killing over a broad range of anti-malarial 
compounds with a variety of different modes of action.
In 2012, a low-throughput assay was developed at Tres 
Cantos, based on the direct measurement of P. falcipa-
rum parasite viability in response to drug treatment over 
time. This methodology quantifies accurately the num-
ber of parasites able to resume a productive growth after 
removal of the drug and addition of fresh erythrocytes. 
The method is based on limiting serial dilutions of treated 
parasites and their culture for up to 28  days to enable 
wells with a single viable parasite to render detectable 
parasitaemia. This standardized assay allows establish-
ment of different parameters, such as the in vitro parasite 
reduction ratio (PRR) and the presence of a lag phase in 
response to treatment with a specific anti-malarial. Nev-
ertheless, this protocol is very labour intensive and time 
consuming and difficult to adapt as a higher throughput 
assay [5].
This study describes the development and validation 
of an in  vitro parasite viability fast assay for identify-
ing rapidly parasiticidal anti-malarial drugs. The meth-
odology has been adapted from a previously described 
invasion assay [11]. Parasite killing kinetics were deter-
mined by first culturing unlabelled erythrocytes with 
P. falciparum in the presence of anti-malarial drugs. 
Immediately following drug removal (at either 24 or 
48  h), new erythrocytes were added which had been 
pre-labelled with intracellular dyes allowing their sub-
sequent identification. Following incubation for 48  h, 
the ability of viable parasites to re-establish infection 
in labelled erythrocytes could then be detected by two-
colour flow cytometry after labelling of parasite DNA, 
i.e., double-stained erythrocytes (with the pre-labelled 
intracellular dye and the parasite DNA dye) result only 
after establishment of new infections by surviving par-
asites. Thus, the capacity of the test anti-malarial drugs 
to eradicate viable parasites within 24 or 48 h could be 
determined.
Although different in  vitro and in  vivo assays have 
been established to measure re-invasion of Plasmo-
dium parasites [11–13], this is the first time that such 
an assay has been used for determining the speed of 
parasite killing by anti-malarial compounds. This meth-
odology provides a breakthrough over existing methods 
as it enables assessment of anti-malarial killing profiles 
48 h following drug treatment and is amenable to auto-
mation. Thus, it should now be possible to interrogate 
large compound libraries to identify the next generation 
of anti-malarial drugs with artemisinin-like killing pro-
files [14–16].
Methods
The final protocol is described below; optimization and 
validation of the assay is described in the “Results”.
Chemicals and materials
Standard anti-malarial drugs were provided by Glaxo-
SmithKline and Medicines for Malaria Venture, except 
azithromycin which was purchased from USP (Rock-
ville, MD, USA). Stock solutions were prepared in DMSO 
at 10  mM. The final DMSO concentration used in the 
experiments (<0.5  %) has no inhibitory effect on para-
site cultures. Carboxylfluorescein diacetate succinimidyl 
ester (CFDA-SE) was purchased from Molecular Probes 
(California, USA), Hoechst 33342 and glutaraldehyde 
solution were purchased from Sigma (St Louis, MO, 
USA).
In vitro culture of Plasmodium falciparum parasites
Plasmodium falciparum strain 3D7A was obtained from 
the Malaria Research and Reference Reagent Resource 
Center (MR4) and cultured using a modification of the 
method described by Trager et al. [17]. Briefly, parasites 
were cultured using RPMI-1640 supplemented with 0.5 % 
Albumax and 150 µM hypoxanthine at 2 % haematocrit 
under an atmosphere of 90  % N2, 5  % CO2, 5  % O2 at 
37 °C. Erythrocytes were obtained from the Spanish Red 
Cross Blood Bank.
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Erythrocyte labelling
Erythrocytes were labelled with CFDA-SE. The protocol 
for erythrocyte labelling was optimized based on modi-
fication of a standard procedure [11]. Optimal conditions 
were incubation of the required volume of erythrocytes 
at 1 % haematocrit in RPMI 1640 with a CFDA-SE con-
centration of 10 µM at 37 °C for 2 h. The suspension was 
washed with complete medium and the labelled eryth-
rocytes re-suspended to 1 % haematocrit with complete 
medium and incubated for 30 min at 37 °C. Finally, cells 
were washed twice with RPMI-1640. Labelled erythro-
cytes were diluted at 1 % haematocrit and stored at 4 °C 
for up to 24 h.
Drug treatment and infection of labelled erythrocytes
Assay methodology is summarized in Fig. 1. The condi-
tions for the viability assay were chosen to mimic those 
used for standard IC50 determination (2  % haematocrit, 
0.5  % parasitaemia with  ≥80  % ring stages) [5]. Asyn-
chronous cultures were incubated under shaking con-
ditions to avoid multiple infections per erythrocyte. A 
culture volume of 50 μL per well with parasites at 4  % 
haematocrit and 0.5  % parasitaemia was dispensed into 
V-bottom, 96-well plates containing 50 μL of complete 
media with previously diluted drugs prepared at 2× their 
final concentration to give a final volume of 100 µL per 
well and a final drug concentration 10× the respective 
50 % inhibitory concentration for P. falciparum (PfIC50); 
this concentration has been shown in previous experi-
ments to avoid sub-optimal drug exposure [5]. For the 
experimental plates, infected erythrocytes were exposed 
to drug for 24 or 48  h using standard incubation tech-
niques at 37 °C. Drug was renewed every 24 h through-
out the treatment period by retiring old media from the 
cultured wells and adding the same volume with fresh 
drug. Drug was removed following either 24 or 48  h of 
exposure. To remove drug, 80 µL of media contain-
ing drug was removed, leaving a 20-µL sample to which 
200 µL of fresh media was added (1/10 dilution). Plates 
were centrifuged for 10  min at 600  g (Beckman Allegra 
X-12R), and 180 µL of media then removed and the 
remaining 20 µL, containing the infected erythrocytes, 
was re-suspended in 100 µL of complete media (1/5 dilu-
tion). Following drug removal, 70 µL of washed infected 
erythrocytes was immediately transferred to a new micr-
otitre plate containing 130 µL of CFDA-SE-labelled, non-
infected erythrocytes (1/3 dilution) at 2 % haematocrit in 
complete media. Plates were incubated for 48 h at 37 °C, 
5 % CO2, 5 % O2, and 90 % N2 to allow new infections to 
develop in labelled erythrocytes as a surrogate measure 
of viable parasites. Control wells contained no drug and 
were exposed for 0  h before progression to the parasite 
invasion step using identical methods to those used for 
experimental plates.
Parasite labelling
Following incubation, parasite cultures were washed with 
phosphate buffer saline (PBS). Plates containing 200 µL 
of cultured parasites were centrifuged and erythrocytes 
suspended with 2 µM Hoechst 33342 in RPMI 1640 and 
incubated at 37 °C for one hour in the dark. To allow the 
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Fig. 1 Scheme showing the in vitro parasite viability fast assay for identification of rapidly parasiticidal anti‑malarial drugs. Parasite killing kinetics 
were determined by first culturing unlabelled erythrocytes with P. falciparum in the presence of anti‑malarial drugs for 24 or 48 h. After remov‑
ing the drug, samples were added to erythrocytes pre‑labelled with intracellular dye to allow their subsequent identification. The ability of viable 
parasites to re‑establish infection in labelled erythrocytes could then be detected by two‑colour flow cytometry after tagging of parasite DNA. Thus, 
double‑stained erythrocytes (with the pre‑labelled intracellular dye and the parasite DNA dye) result only after establishment of new infections 
by surviving parasites. Controls samples containing no drug were progressed through the parasite invasion stage as per experimental samples to 
provide a value representing 100 % parasite viability at time 0
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this method was modified by replacement of the medium 
with Hoechst solution (200 µL) and an incubation of 
20 min. Cells were then fixed with 0.02 % glutaraldehyde 
and stored at 4  °C protected from the light until flow 
cytometry analysis.
Fluorescence‑activated cell sorting (FACS)
Following parasite staining, samples (60 µL), were trans-
ferred to cytometry tubes containing 300 µL of saline 
buffer (final haematocrit 0.3 %) and acquired in a LSRII 
flow cytometer [Becton–Dickinson (BD) Pharmingen, 
San Diego, CA, USA] equipped with a 355  nm 20 mW 
ultraviolet (UV) laser and a 488  nm 15 mW blue laser. 
Hoechst 33342 was excited by a UV laser and detected 
by a 450/40 filter. CFDA-SE was excited by a blue laser 
and detected by a 530/30 filter. Samples were analysed 
using FACSDiva software (Becton–Dickinson). In those 
samples with parasitaemia >0.1 %, the number of eryth-
rocytes acquired was that which assured the gathering of 
at least 1000 events in the region established for infected 
erythrocytes. For parasitaemias  <0.1  %, 8  ×  105 total 
erythrocytes were acquired.
Data analysis and validation
Parasitized CFDA-SE-stained erythrocytes represent 
new infections that have been established from parasites 
surviving drug treatment. Thus, quantification of CFDA-
SE-stained erythrocytes was used to evaluate parasite 
viability following drug treatment. In order to compare 
between different experiments, parasite viability was cal-
culated as the percentage of infected CFDA-SE-stained 
erythrocytes in drug-treated samples at 24 or 48 h versus 
infected CFDA-SE-stained erythrocytes in concurrent 
control samples at time 0, i.e., controls allow normaliza-
tion to a parasite viability of 100 % before drug treatment. 
The results were represented as the mean of this normal-
ized percentage ± the standard error of the mean.
All statistical analyses were performed using the 
GraphPad Prism Software (version 6). The non-paramet-
ric test U-Mann–Whitney was used to compare the two 
groups under comparison. Differences between means 
were considered significant when the P value was <0.05.
Results
Optimization of erythrocyte staining
A previously described protocol for staining erythro-
cytes used erythrocytes labelled with 20  µM CFDA-SE 
for 120 min at 2 % haematocrit [11]. Optimization of this 
method tested decreasing concentrations of CFDA-SE 
(20 µM, 10 µM and 5 µM) at 1 or 2 % haematocrit. Con-
centrations of 10 µM CFDA-SE were sufficient for stain-
ing erythrocytes at 1  % haematocrit and enabled signal 
for detection (Fig. 2a) and labelling was stable for at least 
7  days (Fig.  2b). Erythrocyte labelling incubation times 
were also tested (30, 60 and 120 min at 37  °C), with no 
significant differences in performance (Fig.  2c). Thus, a 
30-min incubation time was selected.
Estimating the rate of new infection by flow cytometry
To confirm that the optimized labelling conditions could 
detect new infections, P. falciparum cultures with 0.5 % 
parasitaemia were grown in the presence of labelled 
erythrocytes for 48 h. The final concentration of labelled 
erythrocytes was two-thirds of the total amount in the 
culture.
Flow cytometry analysis revealed four different eryth-
rocyte populations (Fig.  3a: non-infected non-stained 
erythrocytes (RBC), infected non-stained erythrocytes 
(i-RBC), non-infected stained erythrocytes (RBCCFDA-SE) 
and infected stained erythrocytes (i-RBCCFDA-SE). 
Although i-RBC could result from initial or new infec-
tions of non-stained erythrocytes, all instances of 
i-RBCCFDA-SE must result from new infections. Thus, the 
quantification of i-RBCCFDA-SE can be used to determine 
parasite viability following drug treatment.
As previously described, there was no difference in the 
rate of infection between pre-stained and non-stained 
erythrocytes [11]. In fact, as can be seen in Fig.  3a, the 
ratio between i-RBCCFDA-SE and i-RBC did not differ 
significantly from the ratio between RBCCFDA-SE and 
RBC, indicative that both populations of erythrocytes 
(RBCCFDA-SE and RBC) were equally susceptible to inva-
sion. This is important because, as samples of treated, 
non-labelled erythrocytes are diluted three-fold by add-
ing labelled erythrocytes, as much as two-thirds of the 
new infections can be quantified, but not the approxi-
mately one-third of infections that are produced in 
the initial, non-stained erythrocytes. As no bias was 
detected, the total number of new infections can be 
estimated from the quantified events, i.e., total infec-
tions = 3/2 i-RBCCFDA-SE.
Dynamic range of the assay
The dynamic range of the technique was estimated by 
growing serial dilutions of an initial P. falciparum 3D7A 
culture at 2 % parasitaemia (2 % haematocrit) in the pres-
ence of RBCCFDA-SE for 48  h. As it is shown in Fig.  3b, 
established conditions allowed detection of initial para-
sitaemia levels as low as 0.002 %. Fluorescent quantifica-
tion of i-RBCCFDA-SE was proportional to the number of 
initial parasites in the range of 0.5–0.005 % parasitaemia. 
This dynamic range allows clear differentiation between 
fast-acting compounds and moderate/slow anti-malarial 
agents.
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Assay validation
The assay was validated against four anti-malarial 
agents with well-characterized parasite killing profiles: 
atovaquone and pyrimethamine with a slow/moderate 
rate of killing and chloroquine and artesunate with rapid 
parasite killing. As shown in Fig. 4, the assay was able to 
distinguish between fast- and slow-acting agents within 
48  h after drug treatment. Consequently, 24 and 48  h 
Fig. 2 Optimization of erythrocyte labelling for fluorescence‑activated cell sorting detection. Graphs represent the ratios of mean fluorescence 
intensities from positive cells with respect to the negative population. Error bars represent SEM for three replicates. a Optimization of the assay used 
different concentrations of CFDA‑SE (20, 10 and 5 µM), were tested to stain erythrocytes using 1 or 2 % haematocrit. b Signal intensity by labelled 
erythrocytes remained robust for detection at least 7 days after staining (CFDA‑SE 10 µM, 1 % haematocrit). c To test whether a reduction in incuba‑
tion time could be achieved, different times (30 min, 1 and 2 h) were used for staining erythrocytes with 10 µM CFDA‑SE at 1 % haematocrit
Fig. 3 Fluorescence‑activated cell sorting (FACS) analysis of infected erythrocytes labelled with CFDA‑SE. a DNA staining with Hoechst of parasites 
grown in the presence of CFDA‑SE labelled erythrocytes allows robust detection of four distinct cellular populations. Data are representative of 
two independent experiments. b A P. falciparum 3D7 inoculum grown in standard culture conditions at 2 % haematocrit and 2 % parasitaemia was 
diluted (fourfold serial dilutions), in fresh media containing labelled non‑infected erythrocytes for 48 h. Parasites were labelled with Hoechst and 
fluorescence of i‑RBCCFDA‑SE quantified by FACS. Y axis represents % of i‑RBCCFDA‑SE with respect to total number of RBC. Error bars represent SEM for 
three replicates. Established conditions allow detection of initial parasitaemia as low as 0.002 %
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were identified as the most relevant time points that 
could provide the information required to unequivocally 
identify rapidly parasiticidal compounds. These results 
correlate well with killing rate profiles reported using 
PRR methodology and equally can be attributed to the 
different anti-malarial modes of action tested [5].
Adaptation for medium–high throughput screening
This new methodology is more amenable for medium–
high throughput than the standard PRR assay [5]. Killing 
profiles of different drugs can be determined in only 48 h 
after drug treatment instead of the 3–4  weeks required 
to detect single viable parasite using the limiting dilution 
method [5].
The following modifications were tested: (1) para-
sites were directly stained without removing the culture 
media, and, (2) culture media was replaced by Hoechst 
solution. Additionally, different incubation times (10, 
15 and 20  min) were tested before fixation. An incuba-
tion time of 20  min when the medium was replaced by 
Hoechst solution was selected as optimal, and used for 
subsequent experiments. Evaluation of atovaquone, 
pyrimethamine, chloroquine, and artemisinin using the 
abbreviated format produced similar results as for the 
initial format.
To further validate the abbreviated format, a panel of 
six additional standard anti-malarial molecules was also 
tested (Fig.  5). As expected, mefloquine, piperaquine, 
lumefantrine, halofantrine, and pyronaridine showed a 
fast-acting profile. However, azithromycin did not show 
any effect on parasite viability, consistent with its mode 
of action: azithromycin affects protein synthesis in the 
Plasmodium apicoplast and anti-malarial effects are only 
observed after two cycles of intra-erythrocytic develop-
ment [18].
Furthermore, the abbreviated assay was further vali-
dated and applied to identify novel rapidly parasiticidal 
anti-malarial agents. A set of 20 compounds retrieved 
from the Medicines for Malaria Venture ‘Malaria box’ 
[19], was tested with the parasite viability fast assay and 
the previously described in vitro killing rate assay using 
limiting dilutions [5]. The profiles of rapidly parasiticidal 
anti-malarial agents (chloroquine/artemisinin-like) were 
clearly differentiated from those of slow (atovaquone-
like) or moderate (pyrimethamine-like) compounds and 
results were confirmed independently of the method 
used (Table  1). None of the compounds that displayed 
a fast parasite killing profile was previously known to 
have this property. Thus, these potentially represent new 
avenues of investigation for the development of novel 
anti-malarial agents which have parasite killing kinetics 
similar to artemisinin.
Discussion
Artemisinin resistance is emerging and threatens to 
undermine the effectiveness of anti-malarial therapy. 
Consequently, identifying anti-malarial drugs that could 
succeed artemisinins, and which retain their key property 
of rapid killing of Plasmodium is a priority.
The parasite viability fast assay described in this paper 
is an important step to enable the identification of rap-
idly parasiticidal anti-malarial agents. Recent efforts have 
identified numerous leads for new anti-malarial agents 
[14–16]. However, their evaluation for artemisinin-like 
parasite killing kinetics has been limited, as current 
Fig. 4 Determination of killing rate profile for different classical anti‑
malarial drugs. Plasmodium falciparum viability time‑course profile 
for artesunate, chloroquine, atovaquone, and pyrimethamine at 10 × 
IC50. Fast‑acting anti‑malarial drugs (artesunate and chloroquine) can 
be readily distinguished from moderate or slow‑acting compounds 
(pyrimethamine and atovaquone). The number of viable infected 
erythrocytes was normalized using the number of untreated para‑
sites. Error bars represent SEM for 4–9 replicates
Fig. 5 Two‑time point viability analysis using an abbreviated pro‑
cedure. Plasmodium falciparum cultures were treated with indicated 
drugs and parasites sampled after 24 and 48 h. Medium‑throughput 
conditions allowed discrimination of fast‑acting profiles of pyronari‑
dine, halofantrine, lumefantrine, piperaquine and mefloquine from 
the azithromycin anti‑malarial profile, with parasite killing only in 
the second generation. The number of viable infected erythrocytes 
was normalized using the number of untreated parasites. Error bars 
represent SEM for 4–9 replicates
Page 7 of 8Linares et al. Malar J  (2015) 14:441 
methods are time consuming and cannot easily be scaled 
to screen the thousands of candidate molecules.
The parasite viability fast assay described here was able 
to distinguish between anti-malarial agents with arte-
misinin-like parasite killing kinetics and those that act 
more slowly within 48  h following drug treatment. The 
assay was validated against standard anti-malarial drugs 
with known properties and results correlated well with 
established methods.
The availability of a medium–high throughput assay 
for identifying compounds with artemisinin-like para-
site killing kinetics is a critical step in developing the 
next generation of anti-malarial therapy. Thus, the assay 
described here has been adapted to allow its application 
in medium–high throughput screening and has been 
evaluated against a test set of candidate compounds. 
The methodology lends itself to automation, using sim-
ple incubations and washing steps without the labour-
intensive procedures used for other assays, such as the 
limiting dilution method. Staining stability allows stor-
age, and multiple samples can be simultaneously assayed. 
It is envisaged that the assay could be used for screening 
compound libraries such as the Tres Cantos Antimalarial 
Set (TCAMS), which includes nearly 13,500 compounds. 
The parasite viability kinetic assay could be used with any 
laboratory parasite strain, including adapted ex vivo iso-
lates. This could be particularly relevant in the evaluation 
of artesunate derivatives, as resistant parasites do not 
present any change in terms of in vitro IC50, and complex 
read-outs are required [20, 21].
The parasite viability fast assay described here has a 
less sensitive limit of detection (equivalent to 0.002  % 
parasitaemia) compared with the limiting dilution 
method (equivalent to 0.000005  % parasitaemia) [5]. 
Thus, any compound that elicited a decrease in para-
sitaemia of  >99  % would have the same profile in the 
assay. Although this limit of detection is sufficient to 
differentiate between fast-acting compounds and mod-
erate/slow-acting ones, it cannot resolve differences 
between two fast-acting compounds (e.g., artemisinin 
and chloroquine). A further limitation of the methodol-
ogy is that it cannot evaluate the parasiticidal effects of 
compounds that display a delayed death phenotype, for 
example, azithromycin. However, molecules with such 
a mechanism of action can be identified using standard 
evaluations at 48 and 96  h to prove a shift in the IC50. 
Alternatively, the methodology described here could 
be adapted by extending the incubation time with pre-
labelled erythrocytes to cover two parasite lifecycles.
The parasite viability fast assay offers a rapid, direct 
measurement of parasite killing that does not rely on 
parasite metabolic activity or accumulation of specific 
molecules. Thus, potential bias or artefacts that appear 
when viability and parasite metabolic activity become 
uncoupled are avoided. Although other assays have been 
developed for determining parasite killing kinetics, they 
use indirect measurements to assess parasite viability [8, 
9]. For example, the rapid assay described by Le Manach 
uses a modification of the standard [3H] hypoxanthine 
incorporation assay for IC50 calculations [9]. How-
ever, atovaquone and pyrimethamine do not display the 
expected profile corresponding to their mechanism of 
action [9]. A method that detects shifts in parasite mRNA 
levels has been described by Bahamontes-Rosa [8], but 
can only differentiate between cidal or static behaviours 
and cannot evaluate the speed of parasite killing. The 
method is also laborious and time consuming, reporting 
results at 240 h post-treatment [8].
Exceptional efforts have greatly expanded the pool 
of potential candidate molecules with anti-plasmodial 
activity [14–16]. The main challenge now is to rapidly 
process those candidates to identify the next generation 
of anti-malarial therapy. The parasite viability fast assay 
described here is robust, reliable, rapid, expandable, and 
Table 1 Comparison between the parasite viability kinetic 
assay and the in vitro killing rate assay based on  limiting 
dilutions using compounds from the Medicines for Malaria 
Venture Malaria Box
Fast chloroquine/artemisinin-like (no viable parasites detected after 24 h’ 
treatment), moderate pyrimethamine-like (no viable parasites detected after 
48 h’ treatment), slow atovaquone-like (more than 48 h’ treatment needed to kill 
all parasites)
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could be easily automated. The methodology requires no 
specialized equipment and can be easily implemented in 
standard laboratories. The assay can also be used with 
different parasite strains, offering a flexible research 
tool. The quantification of new infections to assess para-
site viability offers important advantages over existing 
methods, and in particular allows discrimination of rap-
idly parasiticidal anti-malarial candidates that have the 
potential to succeed the artemisinins.
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